U.S., EU Taking New Look At Mitsubishi Tanabe’s MS Drug Gilenya
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma learned two of the world’s drug regulators are taking a new look at the firm’s Gilenya (fingolimod) for treating multiple sclerosis.